• 대한유전성대사질환학회지
• /
• 제13권2호
• /
• pp.104-110
• /
• 2013

Purpose: Phenylketonuria (PKU) is the first inherited metabolic disease of which treatment is known. We performed this study to find out clinical symptoms and prognosis of tetrahydrobiopterin (BH4) responsive PKU patients and genetic relation. Methods: Clinical, biochemical, genetic analysis were done retrospectively in 23 patients diagnosed BH4 responsive PKU in Soonchunhyang University Hospital from March 2000 to September 2012. Results: Patients were classified to mild hyperphenylalaninemia and mild phenylketonuria with initial plasma phenylalanine level below 20 mg/dL. After BH4 loading, blood phenylalanine decrease level ranged between 37% and 99%. Initial treatment with low phenylalanine formula or BH4 was started before 2 month after birth except 2 patients. And one of them resulted in developmental delay in language and social activity. The others showed satisfactory progress without developmental delay. In genetic analysis, of 46 allele, R241C allele mutation was identified most commonly (41%). R241C/A259T, R241C/R243Q, R241C/V388M, R241C/T278I was detected in 5 (21.7%), 3 (13%), 2 (8%), 2 (8%) patients, respectively. Conclusion: R241C mutation was detected most frequently in this study group and R243Q mutation which is known to be prevalent in Korean PKU patients was found in 4 patients (8.6%). Early diagnosis and treatment is important in PKU patients.

• 대한유전성대사질환학회지
• /
• 제15권2호
• /
• pp.55-58
• /
• 2015

Tetrahydrobiopterin ($BH_4$) can normalize blood phenylalanine (Phe) levels in $BH_4$ deficiency, but typically not in phenylketonuria (PKU). In 1999, Kure et al. reported that some PKU patients showed decreased blood Phe levels after $BH_4$ loading, and thereafter, those PKU patients were identified by neonatal PKU screening. A natural cofactor for phenylalanine hydroxylase (PAH) is a 6R-isomer of $BH_4$, which is first synthesized in Japan as Sapropterin dihydrochloride (Biopten$^{(R)}$) in 1982. In Japan, Biopten$^{(R)}$ is first approved for the treatment of $BH_4$ deficiency in 1992, and then for $BH_4$-responsive PAH deficiency (BPKU) in 2008. The discovery of BPKU has vast clinical implications. After Biopten$^{(R)}$ (Kuvan$^{(R)}$) is available for the treatment of BPKU, the QOL of both patients and their families were improved very much, since the serum phenylalanine levels were controlled within 4 mg/dL by $BH_4$ mono-therapy with a normal diet or $BH_4$ combined use of mild phenylalanine-restricted diet. Biopten$^{(R)}$ therapy in patients with BPKU is highly efficacious (70%) at maintaining serum Phe levels within recommended control range and provides excellent safety at least average use period of 10 years (range, 1-17 years) with no unwarranted side effects in Japan. In addition it has been confirmed that sapropterin therapy initiated before 4 years of age was very effective to maintain plasma Phe levels within the favorable range and was safe in Japanese patients with BPKU.

• Journal of Genetic Medicine
• /
• 제5권1호
• /
• pp.26-33
• /
• 2008

목 적 : 페닐케톤뇨증은 상염색체 열성으로 유전되는 아미노산 대사질환으로 PAH와 조효소인 $BH_4$의 활성이 저하되어 발생한다. 본 연구에서는 PAH 유전자 돌연변이와 임상양상과의 연관성을 조사하였고 PAH DNA 변이의 국가간의 차이를 분석하였다. 방 법 : 페닐케톤뇨증 환자와 환자 가족의 동의하에 DNA를 말초혈액의 백혈구에서 분리하여 PAH 유전자를 PCR을 통해 증폭하여 유전자 서열을 분석하였고 PAH 돌연변이가 하나의 대립유전자에서만 발견이 되거나 없는 경우는 분석된 서열을 MLPA를 시행하여 분석을 하였다. 결 과 : 유전자 검사를 시행한 102명의 대립유전자 204개 중 199개의 돌연변이가 발견되어 97%의 검출률을 보였다. 발견된 돌연변이는 총 44가지의 유전자형으로 9개는 novel missense mutation이었고 1개는 novel splice site mutation이었다. 가장 많은 대립 유전자형은 R243Q와 $IVS4^{-1}$G>A로 각각 13.1%와 11.6%를 나타내었다. 전형적 페닐케톤뇨증에서는 R243Q와 $IVS4^{-1}$G>A가 각각 14.2%를 차지하였고 $BH_4$ 반응형 페닐케톤뇨증의 경우에는 R241C가 33.3%, 양성 고페닐알라닌혈증이 R241C가 40%에서 나타났다. $BH_4$ 반응형 페닐케톤뇨증의 경우에는 약물 치료만으로 조절이 되는 환자에서 T278I와 V388M mutation이 발견되었고 약물 치료만으로 조절이 되지 않고 식사요법을 병행해야하는 환자들에서만 K95del과 A447P의 돌연변이가 나타났다. 그리고 2004년 이전에는 동양인에게서 A259T 대립유전자 돌연변이가 발견되지 않은 것으로 보고되었으나 본 연구에서는 10.1%에서 발견되었다. 결 론 : 페닐케톤뇨증과 관련된 새로운 유전자 변이들이 발견되고 있으며 $BH_4$에 반응하는 유전자 변이들의 유전자형들이 확인되면서 PAH 유전자 분석은 페닐케톤뇨증 환자에서 진단, 유전상담, 식사 요법과 치료 계획 수립에 기여할 것이다.